Explaining Elephants’ Cancer Resistance

Two studies reveal that the giant mammals have dozens of extra copies of a cancer-preventing gene.

By | October 13, 2015

WIKIMEDIA, CHRISTOPHER MICHELWith about 100 times as many cells as a human, a 4,800-kilogram African elephant should, in theory, be more prone to accruing mutations that cause one of those cells to grow out of control. But elephants and other large mammals have surprisingly low rates of cancer, despite living for decades. As Joshua Schiffman, a pediatric oncologist at the University of Utah’s Huntsman Cancer Institute in Salt Lake City, and his colleagues found in a paper published last week (October 8) in JAMA, fewer than 5 percent of captive elephants worldwide die from cancer.

“Long-lived animals with lots of cells should all be dropping dead of cancer,” Schiffman told Science. “But they don’t or they’d go extinct.”

To understand why elephants are apparently cancer resistant, Schiffman and his colleagues scoured the genome of an African elephant and found 40 copies of the p53 gene, known to be important in cancer prevention. The Asian elephant genome contains between 30 and 40 copies of p53. Humans harbor only two copies of the gene. But elephant cells were no better at repairing DNA damage than human cells, in vitro experiments revealed. Instead, the researchers suggested that p53 helps elephants kill off precancerous cells before they become problematic.

Another study published last week (October 6) on the preprint server BioRxiv also found dozens of copies of p53 in the elephant genome, as well as in two extinct species of mammoth. Coauthor Vincent Lynch of the University of Chicago speculated that p53 duplicated as elephant ancestors began to grow in size, but noted that this is likely not the only mechanism to explain the lineage’s cancer resistance.

Cancer biologist Mel Greaves of the Institute for Cancer Research in London agreed. “What would happen if elephants smoked and had a bad diet,” he told Nature. “Would they really be protected from cancer? I doubt it.”

Add a Comment

Avatar of: You



Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo

Popular Now

  1. UC Berkeley Receives CRISPR Patent in Europe
    Daily News UC Berkeley Receives CRISPR Patent in Europe

    The European Patent Office will grant patent rights over the use of CRISPR in all cell types to a University of California team, contrasting with a recent decision in the U.S.

  2. DNA Replication Errors Contribute to Cancer Risk
  3. Should Healthy People Have Their Exomes Sequenced?
    Daily News Should Healthy People Have Their Exomes Sequenced?

    With its announced launch of a whole-exome sequencing service for apparently healthy individuals, Ambry Genetics is the latest company to enter this growing market. But whether these services are useful for most people remains up for debate.  

  4. Rethinking a Cancer Drug Target
    Daily News Rethinking a Cancer Drug Target

    The results of a CRISPR-Cas9 study suggest that MELK—a protein thought to play a critical role in cancer—is not necessary for cancer cell survival.

Business Birmingham